Medical Oncology

, 30:549

MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery

  • Shan Li
  • Jing Gao
  • Jin Gu
  • Jiajia Yuan
  • Dong Hua
  • Lin Shen
Original Paper

DOI: 10.1007/s12032-013-0549-0

Cite this article as:
Li, S., Gao, J., Gu, J. et al. Med Oncol (2013) 30: 549. doi:10.1007/s12032-013-0549-0

Abstract

To investigate the role of miR-215 in the relapse following radical surgery of colorectal cancer patients. The clinical data and surgical frozen tumor tissues were retrospectively collected from 125 stage II/III colorectal cancer patients, which contained 60 patients who relapsed and 65 patients who did not relapse within 3 years after surgery. The expression of miR-215 was determined by real-time PCR, and the relationship between miR-215 expression and the relapse was analyzed statistically. miR-215 was downregulated in relapsed patients compared to nonrelapsed patients (P = 0.001). The low expression of miR-215 was significantly correlated with a high probability of 3-year relapse (P = 0.001), which was more obvious in stage III patients (P < 0.001). The multivariate analysis showed that miR-215 expression could function as an independent predictive marker for relapse. It seemed that patients with high expressions of miR-215 could benefit from 5-fluorouracil-containing adjuvant chemotherapy without significant difference, whereas this phenomenon was reverse in patients with low expressions of miR-215. Our study highlighted for the first time that miR-215 could function as a potential predictive marker for relapse following radical surgery of colorectal cancer, and the possible correlation between miR-215 and 5-fluorouracil-containing adjuvant chemotherapy would be validated in the future.

Keywords

miR-215 Colorectal cancer Relapse 5-FU Adjuvant chemotherapy 

Supplementary material

12032_2013_549_MOESM1_ESM.tif (3.8 mb)
Supplementary material 1 (TIFF 3858 kb)
12032_2013_549_MOESM2_ESM.tif (3.9 mb)
Supplementary material 2 (TIFF 4004 kb)

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Shan Li
    • 1
    • 4
  • Jing Gao
    • 1
  • Jin Gu
    • 2
  • Jiajia Yuan
    • 1
  • Dong Hua
    • 3
  • Lin Shen
    • 1
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI OncologyPeking University Cancer Hospital and InstituteHaidian District, BeijingChina
  2. 2.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Colorectal SurgeryPeking University Cancer Hospital and InstituteBeijingChina
  3. 3.Department of Medical OncologyThe Fourth People’s Hospital of WuxiWuxiChina
  4. 4.Beijing Shijitan HospitalCapital Medical UniversityBeijingChina